The European Medicines Agency and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) have awarded the first 'ENCePP study' seal to an observational study investigating the "long-term outcomes and adverse events of therapy with inhaled corticosteroids, long-acting beta-2-agonists and anticholinergic drugs in hospitalised patients with Chronic Obstructive Pulmonary Disease (COPD)".
The study is coordinated by the Department of Epidemiology, Lazio Regional Health Service.
For further information see: Press release published on 1st October 2010
Details
- Publication date
- 1 October 2010
- Author
- European Medicines Agency